Bouvet, J.; Segouffin Cariou, C.; Oberli, F.; Guiot, A.-L.; Cupillard, L.
A New Licensed Quadrivalent Antileptospiral Canine Vaccine Prevents Mortality, Clinical Signs, Infection, Bacterial Excretion, Renal Carriage and Renal Lesions Caused by Leptospira Australis Experimental Challenge. Vaccines 2024, 12, 1104.
https://doi.org/10.3390/vaccines12101104
AMA Style
Bouvet J, Segouffin Cariou C, Oberli F, Guiot A-L, Cupillard L.
A New Licensed Quadrivalent Antileptospiral Canine Vaccine Prevents Mortality, Clinical Signs, Infection, Bacterial Excretion, Renal Carriage and Renal Lesions Caused by Leptospira Australis Experimental Challenge. Vaccines. 2024; 12(10):1104.
https://doi.org/10.3390/vaccines12101104
Chicago/Turabian Style
Bouvet, Jérôme, Carine Segouffin Cariou, Frantz Oberli, Anne-Laure Guiot, and Lionel Cupillard.
2024. "A New Licensed Quadrivalent Antileptospiral Canine Vaccine Prevents Mortality, Clinical Signs, Infection, Bacterial Excretion, Renal Carriage and Renal Lesions Caused by Leptospira Australis Experimental Challenge" Vaccines 12, no. 10: 1104.
https://doi.org/10.3390/vaccines12101104
APA Style
Bouvet, J., Segouffin Cariou, C., Oberli, F., Guiot, A.-L., & Cupillard, L.
(2024). A New Licensed Quadrivalent Antileptospiral Canine Vaccine Prevents Mortality, Clinical Signs, Infection, Bacterial Excretion, Renal Carriage and Renal Lesions Caused by Leptospira Australis Experimental Challenge. Vaccines, 12(10), 1104.
https://doi.org/10.3390/vaccines12101104
